Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study

Novo Nordisk (NOVOb.CO) said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.